|
| Status |
Public on Jun 11, 2020 |
| Title |
Gene expression changes following dihydrotestosterone (DHT) treatment in HCI-009 PDXs |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
Triple-negative breast cancer (TNBC) is aggressive and difficult, and few targeted therapies are available to treat this patient population. The androgen receptor (AR) has emerged as a potential target in breast cancer. Newer generation AR inhibitors, such as Seviteronel (Sevi), are unique in their ability to inhibit AR both directly and by blocking upstream androgen synthesis. The purpose of this study was to investigate the pre-clinical activity of Sevi in TNBC and further explore the effectiveness of targeting both androgen biosynthesis and AR activity in combination with other downstream acting agents. AR overexpressing (AR+) TNBC cell lines, xenografts and androgen responsive patient-derived xenograft (PDX) models were using to show how effectively Sevi inhibits AR activity and cell/tumor proliferation. Single cell RNA-sequencing of the AR+ cell line MDA-MB-453 illustrated heterogeneity in AR levels and identified cell cycle pathway activation in ARHigh versus ARLow expressing cells. Combination treatment with the cell cycle CDK4/6 inhibitor abemaciclib and Sevi showed synergy in AR+ TNBC cells and increased effectiveness, compared to each drug alone, in an AR+ TNBC xenograft model. While cell cycle inhibitors have been approved for use in hormone-receptor positive breast cancer, our studies suggest that these drugs may be equally effective in AR+ TNBC cells, especially when combined with AR antagonists. Implications. These data suggest that targeting AR signaling at multiple points throughout the pathway may be an effective was to treat patients with AR+ TNBC.
|
| |
|
| Overall design |
HCI-009 is a TNBC PDX originally developed in the laboratory of Dr. Alana Whelm and propagated in immunodeficient NOD/SCID/gamma (NSG) mice. In the DHT experiment (n=3-4 mice per group), cycling female NSG mice were implanted with cellulose control or slow release 8mg DHT pellets. PDX tumor portions were bilaterally, orthotopically injected into the mammary fat pads, and tumors were measured weekly by caliper for 9 weeks.
|
| |
|
| Contributor(s) |
Christenson JL, O'Neill KI, Williams MM, Spoelstra N, Jones K, Trahan GD, Van Patten E, Eisner JR, Richer JK |
| Citation(s) |
34736512 |
| |
| Submission date |
Jun 10, 2020 |
| Last update date |
Nov 10, 2021 |
| Contact name |
Jessica Christenson |
| E-mail(s) |
jessica.christenson@cuanschutz.edu
|
| Organization name |
University of Colorado Anschutz Medical Campus
|
| Department |
Pathology
|
| Lab |
Jennifer Richer
|
| Street address |
12800 E. 19th Ave.
|
| City |
Aurora |
| State/province |
CO |
| ZIP/Postal code |
80045 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL24676 |
Illumina NovaSeq 6000 (Homo sapiens) |
|
| Samples (7)
|
|
| Relations |
| BioProject |
PRJNA638700 |
| SRA |
SRP266849 |
Less...
More...